Metastatic malignant melanoma to the gallbladder: Case report and review of the literature

G. RIVA1, M. VILLANOVA1, A. ECCHER1, C. LUCHINI1, F. MOUTTA2, R. BERNASCONI1, M. BARBARESCHI3
1 Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Italy; 2 Department of G.F. Ingrassia, Section of Anatomic Pathology, University of Catania; 3 Department of Histopathology, “S. Chiara” Hospital, Trento APSS, Trento, Italy

Key words
Melanoma • Gallbladder • Metastasis

Summary
Correspondence
G. Riva, A. Stefani Square 1, 37126 Verona, Italy - E-mail: riva23@hotmail.it

Case report
An 86-year-old man went to medical observation complaining progressive nausea, vomiting, and increasing right upper quadrant pain. On physical examination, he had a palpable, distended, tender GB. The haematological tests revealed an elevation of her white blood cell count (WBC) to 14 500/mm3 with neutrophilia. Liver function studies were altered: P-AST: 66 U/L; P-ALT: 57 U/L; P-ALP: 503 U/L P-GGT: 833 U/L; P-bil tot: 27.2 μmol/L; P-bil dir: 17.8 μmol/L.
Ultrasound examination of the GB and MR imaging did not demonstrate lithiasis but a polypoid mass without acoustic shadowing. The patient underwent open cholecystectomy the following day. In his past medical history he suffered of malignant melanoma (Clark level III) resected from his left leg 17 years ago. The GB was removed together with the lymph node along the cystic duct. At the sampling of the specimen a dark mass with a polypoid aspect, adherent to the mucosae and projecting itself into the lumen, was found. This lesion measured 1.4 x 2 x 3 cm and presented an homogeneous consistence. At the histological examination, the mucosae was diffusely infiltrated by epithelioid and spindle cells; the epithelium was partially eroded and no junctional activity was apparent; the cystic duct lymphnode was negative. The neoplastic cells were large, hyperchromatic and had irregular nuclei, as well as a moderate eosinophilic cytoplasm, without melanic pigment. Nucleoli were prominent with numerous pseudoinclusions. Neoplastic cells were strongly reactive to antibodies S-100 protein, MART-1, SOX-10 and vimentin. Only weak positivity for HMB-45 was found (Fig. 1). The postoperative course was uneventful and the patient was discharged on postoperative day 5. The final pathological report was that of metastatic melanoma to the GB. 18F-FDG PET-TC was then performed to exclude others metastatic involvement.

Discussion
MM is the most common neoplasm to metastasize to the gastrointestinal tract. Autopsy reports estimate that up to 15% of these patients also have GB metastases, and MM accounts for up to 60 per cent of metastatic lesions to the GB. Only 2 to 4% of patients with melanoma will be diagnosed with gastrointestinal metastasis during the course of their disease. The most common sites of gastrointestinal metastases include the small bowel
METASTATIC MALIGNANT MELANOMA TO THE GALLBLADDER. CASE REPORT AND REVIEW OF THE LITERATURE

(35-67%), colon (9-15%) and stomach (5-7%), with a median survival of 6-10 months after surgery. The time from the diagnosis of MM to GB metastasis varies between 3 and 13 years. Just as in our case solitary GB metastasis of MM is rare and generally originates from skin melanoma and the fact that typically patients do not present until they are symptomatic is further complicating the diagnosis. Primary gastrointestinal melanoma is rare and most gastrointestinal melanomas are metastatic from primary cutaneous lesions. Although MM usually originates from the skin, it can also develop from squamous mucous membranes, uvea, retina, and leptomeninges. To distinguish primary from metastatic melanoma, a junctional component, formed by clustered melanocytes at the mucosa-submucosa junction adjacent to the tumoral mass, must be identified and defined by immunoreactivity. This is the most conclusive histologic evidence for primary melanomas in unusual locations. McFadden comparing primary and metastatic biliary MM found that the two groups displayed remarkable similarity with regard to pathologic findings. According to histogenesis, melanoblasts have not yet been demonstrated in organs of endodermal origin and GB is an endodermal derivative. On the other hand, non neoplastic melanoblasts resulting from migration of melanin-producing cells from the neural crest to endodermal derivatives during embryologic development explains the presence of melanocytes within their mucosa and supports the possibility of developing primary melanomas at these sites. Furthermore 70-80% percent had extrabiliary sites of metastasis at some time in the course of their disease, tending to refute the impression of “primary” biliary melanoma. Melanoma in the gallbladder is much more likely to have metastasized from a regressed skin primary than to have arisen de novo. Criteria proposed by the specific literature for distinguishing primary from secondary GB melanoma include the exclusion of previous primitive melanoma, absence of synchronous involvement of other sites, the unicity of lesion, its polypoid or papillary shape and the presence of a junctional melanocitary component. In some cases ultrasound may document metastatic lesions within the GB. However, polypoid lesions in the lumen present a focal thickening of the wall without acoustic shadowing.
due to their lower density in relation with gallstones 13. Abdominal ultrasound remains the modality of choice in studying GB pathology and has the ability to define metastatic lesions 1. On MR imaging it’s possible to appreciate a diffusely thickened wall 14 15. An F-18-fluoro-2-deoxyglucose (F-18 FDG) whole-body positron emission tomography/computed tomography (PET/CT) study is often requested with the purpose of staging 15. Most patients with melanoma metastatic to the GB are asymptomatic, and the most common symptom is acute cholecystitis due to cystic duct obstruction 1. MM is a neoplasm with an often unpredictable course and metastases potentially affecting all organs. The occurrence of metastasis in the GB is rare and has only been reported in the literature exceptionally 16 but constitutes the most common metastatic lesion involving this organ 9 17 18. In the literature there are only few reports on this topic in living patients 17. Isolated metastatic disease to the biliary system is accompanied by obstructive jaundice if the tumor is located in the common bile duct or by upper abdominal pain mimicking symptomatic cholecystolithiasis, but asymptomatic cases were also described 19. In case of metastatic lesions of the gallbladder, treatment options depend on the extension of the disease and on the clinical status of the patient, the only agreement is that surgery is the mainstay treatment 20. In patients with melanoma metastatic to the gallbladder, overall survival is determined more by the biology of the disease than treatment. In the presence of symptoms, cholecystectomy is often effective palliation in carefully selected patients 21. The surgical management seems to be indicated for patients with isolated and resectable GB metastases to avoid symptoms or tumor complications. Laparoscopic approach with gentle manipulation, avoidance of perforation, and use of a retrieval bag for the removal of the gallbladder should be practiced to help minimize the chance of mechanical exfoliation or implantation of malignant cells 22. However open surgery has also a comitant diagnostic purpose because gives the possibility of manual exploration of abdominal cavity, useful particularly to reveal bowel metastatic lesions2 and in order to avoid trocar recurrence and perforation of the gallbladder, Christou et al. suggest open cholecystectomy rather than laparoscopic, also to extend the detection of liver or other secondaries unidentified preoperatively 23 24. Laparoscopic cholecystectomy without a lymphadenectomy is emerging as the preferred approach for this metastatic deposit 25. The “gold-standard” treatment of metastatic melanoma of the gallbladder remains unclear 26. The role of systemic adjuvant therapies still remain uncertain for malignant melanoma of the GB as suggested by the most recent NCCN 2013 guidelines. Recently the advent of the immunotherapy drug such as b-raf inhibitor have shown to be more effective and improved survival in phase III trials 27. However, because of the limited data available in long standing patients with metastatic disease, further studies are needed.

References


